• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Pharmacokinetics and biotransformation of 3-cyan-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in the rat].

作者信息

Vagaday M, Kunter U, Labes D, Hagen V, Böhme B, Franke P

机构信息

Pharmakologische Forschungsgesellschaft Biopharm GmbH, Berlin.

出版信息

Pharmazie. 1994 Jan;49(1):41-7.

PMID:8140129
Abstract

A sensitive isocratic HPLC method for the analysis of AWD 122-14 (1) in plasma and urine was developed. The extraction was processed on-line on a short column. The pharmacokinetics of 1 was studied in rats. The plasma concentration-time course was described by an 1-compartment-model. The pharmacokinetic parameters were estimated. The absorption and elimination of 1 are relatively fast. A single oral dose (D = 1 x 10(-5) mol/kg) was rapidly absorbed (absorption rate constant: kI = 6.85 h-1). The elimination rate constant is kE = 1.59 h-1. The absolute bioavailability of a single oral dose equals 11%. In rats 1 is mainly metabolized. Less than 5% of the dose is excreted in the urine as unchanged drug. The chemical structures of 10 of the 12 isolated metabolites were determined using high-resolution mass spectrometry.

摘要

相似文献

1
[Pharmacokinetics and biotransformation of 3-cyan-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in the rat].
Pharmazie. 1994 Jan;49(1):41-7.
2
[Pharmacokinetics of afobazole in rats].阿伏苯唑在大鼠体内的药代动力学
Eksp Klin Farmakol. 2007 Mar-Apr;70(2):59-64.
3
Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.新型血栓素A2受体拮抗剂雷马曲班在动物体内的药代动力学和代谢。首次通讯:单次给药于大鼠和犬后的吸收、血浆浓度、代谢及排泄情况
Arzneimittelforschung. 1997 Aug;47(8):928-38.
4
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.新型选择性p38α抑制剂6-(4-(2,5-二氟苯基)恶唑-5-基)-3-异丙基-[1,2,4]-三唑并[4,3-a]吡啶的临床前药代动力学与代谢:在临床前物种及人肝微粒体中活性代谢物的鉴定
Biopharm Drug Dispos. 2006 Nov;27(8):371-86. doi: 10.1002/bdd.520.
5
Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.大鼠、犬和猴单次口服给予[羰基-14C]枸橼酸莫沙必利后的吸收、分布及排泄情况。
Arzneimittelforschung. 1993 Oct;43(10):1084-94.
6
[Pharmacokinetics of afobazole metabolite (M-11) in rats].阿伏苯唑代谢物(M-11)在大鼠体内的药代动力学
Eksp Klin Farmakol. 2011;74(7):22-6.
7
Preliminary pharmacokinetics of a new pyridopyrimidine derivative.一种新型吡啶并嘧啶衍生物的初步药代动力学
Arzneimittelforschung. 1991 Jun;41(6):640-4.
8
Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.口服直接Xa因子抑制剂利伐沙班在大鼠、犬和人类体内的代谢及排泄情况。
Drug Metab Dispos. 2009 May;37(5):1056-64. doi: 10.1124/dmd.108.025569. Epub 2009 Feb 5.
9
Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.给斯普拉格-道利大鼠静脉注射、口服和气管内给予3H-醋酸艾洛米松后的药代动力学、蛋白结合及代谢情况
Arzneimittelforschung. 1998 Apr;48(4):371-8.
10
Pharmacokinetics of higenamine in rabbits.去甲乌药碱在兔体内的药代动力学
Biopharm Drug Dispos. 1996 Dec;17(9):791-803. doi: 10.1002/(SICI)1099-081X(199612)17:9<791::AID-BDD993>3.0.CO;2-T.